Physician profile
Maria E Moran
NPI 1114408135
$4,630.15
in general payments reported to CMS, 2019-2025
40 companies · $1,995 in 2025
The $1,995 reported for 2025 was more than what 94% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $265 · 2022: $13.70 · 2023: $1,368 · 2024: $988 · 2025: $1,995.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,240 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,240.13 |
| Education | $111.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,001.60 | 2023-2025 | Rexulti, Nuedexta, Jynarque |
| Abbvie INC. | $389.44 | 2023-2025 | |
| Emd Serono, INC. | $365.12 | 2023-2025 | Mavenclad |
| Lundbeck LLC | $333.82 | 2023-2025 | Vyepti, Rexulti |
| Pfizer INC. | $294.53 | 2023-2025 | |
| Ucb, INC. | $222.87 | 2024-2025 | Briviact, Rystiggo, Zilbrysq |
| Neurelis, INC. | $210.76 | 2024-2025 | Valtoco |
| Alexion Pharmaceuticals, INC. | $199.26 | 2024-2025 | Ultomiris |
| Idorsia Pharmaceuticals US INC | $190.54 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $190.00 | 2021-2025 | Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $137.53 | 2023-2025 | Emgality, Kisunla, Amyvid |
| Amgen INC. | $114.88 | 2021-2024 | Aimovig, Repatha |
| Astrazeneca Pharmaceuticals LP | $110.97 | 2023-2025 | Wainua, Farxiga |
| Biogen, INC. | $103.06 | 2021-2025 | Vumerity, Tysabri |
| Neurocrine Biosciences, INC. | $91.11 | 2021-2024 | Ingrezza, Ongentys |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Moran listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.